Christian de Mey

ORCID: 0000-0001-8855-7193
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Analytical Methods in Pharmaceuticals
  • Heart Rate Variability and Autonomic Control
  • Blood Pressure and Hypertension Studies
  • Hemodynamic Monitoring and Therapy
  • Cardiovascular Syncope and Autonomic Disorders
  • Pharmacology and Obesity Treatment
  • Cardiac electrophysiology and arrhythmias
  • Pharmaceutical studies and practices
  • Respiratory and Cough-Related Research
  • Pharmacological Effects and Assays
  • Pharmacogenetics and Drug Metabolism
  • Hormonal and reproductive studies
  • Antibiotics Pharmacokinetics and Efficacy
  • Asthma and respiratory diseases
  • Urinary Bladder and Prostate Research
  • Analytical Chemistry and Chromatography
  • Amino Acid Enzymes and Metabolism
  • Renal function and acid-base balance
  • Liver Disease Diagnosis and Treatment
  • Inhalation and Respiratory Drug Delivery
  • Statistical Methods in Clinical Trials
  • Cardiovascular Function and Risk Factors
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Cardiovascular and exercise physiology
  • Non-Invasive Vital Sign Monitoring

Clinical Research Services
1998-2015

University Hospital Cologne
2015

Pharmac
2011

Al-Ahram Center for Political and Strategic Studies
2010

Klinikum Leverkusen
2008

Friedrich Schiller University Jena
2002

Desitin Arzneimittel (Germany)
2001

Early Intervention Foundation
2001

University Medical Center of the Johannes Gutenberg University Mainz
1992-1997

Johannes Gutenberg University Mainz
1992-1997

Myrtol standardized (Gelomyrtol<sup>®</sup> forte) is a phytotherapeutic extract (distillate) consisting mainly of three monoterpenes: (+)α-pinene, d-limonene and 1,8-cineole. Objective: This study describes compares the efficacy, safety tolerability 2-week treatment with myrtol stand. (4 × 300 mg, day 1-14), cefuroxime (CAS 55268-75-2) (2 250 mg daily for 1-6), ambroxol 18683-91-5) (3 30 1-3, 2 days 4-14) matched placebo in acute bronchitis. Patients: 676 male female outpatients, aged...

10.1055/s-0031-1300276 article EN Arzneimittelforschung 2011-12-27

Red vine leaf extract (RVLE) is a herbal medicine containing several flavonoids, with quercetin-3-O-ß-glucuronide and isoquercitrin (quercetin-3-O-ß-glycoside) as the main components. Objective – To assess efficacy safety of once-daily doses 360 720 mg RVLE (pharmaceutical code AS 195; Antistax® Venenkapseln) compared to placebo in patients stage I incipient II chronic venous insufficiency (CVI). Design A 12-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center...

10.1055/s-0031-1300174 article EN Arzneimittelforschung 2011-12-28

GeloMyrtol® forte (Myrtol®) is a phytomedicine obtained by distillation from essential oils. The trial was conducted to confirm the efficacy of Myrtol® in treatment acute bronchitis.Patients with bronchitis and without confounding co-morbidity or co-medication were randomly assigned either 300 mg 4 times daily matched placebo double-blind, parallel-group fashion. Signs symptoms evaluated investigator at baseline after 7, 10 14 days treatment; intake medication, wellbeing recorded patient...

10.1055/s-0032-1331182 article EN Drug Research 2013-01-08

Patients with primary or secondary immunodeficiency (PID SID) face increased insecurity and discomfort in the light of COVID-19 pandemic, not knowing if to what extent their comorbidities may impact course a potential SARS-CoV-2 infection. Furthermore, recently available vaccination options might be amenable effective for all patients this heterogeneous population. Therefore, these often rely on passive immunization plasma-derived, intravenous subcutaneous immunoglobulin (IVIG/SCIG). Whether...

10.1007/s40259-021-00511-9 article EN cc-by-nc BioDrugs 2021-11-29

This multicenter, placebo-controlled, double-blind, randomized parallel-group trial was conducted to investigate the efficacy and tolerability of myrtol standardized (MYS, forte, 3 × 300 mg) in long-term treatment patients with chronic bronchitis during winter. 246 received investigational treatments (MYS: 122, placebo: 124) for at least 1 month; 215 subjects (110 under MYS 105 placebo) were evaluable terms (exacerbation rate, need antibiotics, symptom scores general well-being)...

10.1055/s-0031-1300426 article EN Arzneimittelforschung 2011-12-28

Sore throat is the hallmark of acute pharyngitis. Although usually caused by viral infections, it frequently treated with antibiotics. Such inappropriate use antibiotics might best be challenged offering efficacious and safe symptomatic pain relief instead. However, there need for robust evidence to support such alternatives. Presently, from randomised, placebo-controlled, double-blind clinical trials (RCT) local anaesthetic ambroxol (CAS 23828-92-4) in treatment sore being reviewed. This...

10.1055/s-0031-1296557 article EN Arzneimittelforschung 2011-12-19

Two confirmatory clinical trials were performed to investigate the efficacy and tolerability of ambroxol lozenges at doses 20 mg 30 relative placebo in relieving symptoms sore throat least moderately severe intensity patients suffering from oro-pharyngeal catarrh accompanied by pain on swallowing, feeling scratchiness, burning urge cough. Description comparison containing or hydrochloride (trans-4-[(2-amino-3,5-dibrom-benzyl)amino]cyclohexano hydrochloride, CAS 18683-91-5) acute throat,...

10.1055/s-0031-1299889 article EN Arzneimittelforschung 2011-12-26

The effects of a single oral dose 25 mg carvedilol on the plasma and urinary kinetics digoxin after an intravenous 0.5 dose, were investigated in two separate double‐blind, placebo‐controlled, period‐balanced cross‐over studies healthy male subjects. Carvedilol increased mean maximum concentration area under time‐curve when administered orally. virtually confined to first 4 h dosing, apparent terminal disposition rate constant was not changed. did alter intravenously digoxin.

10.1111/j.1365-2125.1990.tb03668.x article EN British Journal of Clinical Pharmacology 1990-04-01

1 The binding of epoprostenol (prostacyclin, PGI2) to isolated fractured human platelets has been studied using tritiated PGI2. 2 High and low affinity sites for PGI2 have identified (Kd values = 16 382 nM). 3 Analysis the prostacyclin‐dependent activation adenylate cyclase suggests that enzyme is mediated by high site. 4 Platelet receptor are unchanged in diabetic normal platelets. 5 This work hyperaggregability not due any alteration platelet prostacyclin numbers or their activation.

10.1111/j.1365-2125.1983.tb01467.x article EN British Journal of Clinical Pharmacology 1983-01-01

The isolated and perfused kidney of the mature spontaneously hypertensive rat (SHR) exhibits an increased vascular reactivity a delayed tachyphylaxis to 5-hydroxytryptamine, when compared weight-matched normotensive animals. To evaluate influence duration state on these differences, 5-hydroxytryptamine was determined in kidneys from age-matched rats 3.5, 6 12 months age. Responses increasing doses were compared. At all ages responses agonist greater SHR than control rats. In rats,...

10.1161/01.hyp.3.6.718 article EN Hypertension 1981-11-01

Study objective The study was performed to evaluate the relative sensitivity of various noninvasive methods detect and describe systolic cardiovascular effects stepwise increasing doses isoproterenol: two-dimensional left ventricular echocardiography (main variable, ejection fraction), ACVF (attenuation compensated volume flow)–dual-beam Doppler echoaortography (time-averaged mean velocity), electrical impedance cardiography [(dZ/dtmax)/RZ index], time intervals from mechanocar-diography...

10.1038/clpt.1992.199 article EN Clinical Pharmacology & Therapeutics 1992-12-01

Objective To evaluate the pharmacodynamic properties of carvedilol across a broad range doses in relation to its enantiospecific kinetics and adrenergic receptor occupancies, relative placebo propranolol. Methods Twelve healthy male subjects were investigated on six separate occasions at least 1 week apart when they received either single peroral dose 40 mg propranolol, 12.5, 25, 50, or 100 carvedilol, placebo. The extensively profiled supine rest, underwent bicycle ergometry before 2, 4, 6,...

10.1038/clpt.1994.34 article EN Clinical Pharmacology & Therapeutics 1994-03-01

Acute oro-pharyngeal catarrh is characterised by mild to severe sore throat, such as pain on swallowing, feeling of scratchiness, burning and urge cough. The present study was conducted explore whether the test compound going show clinical relevance a suitable medication for relief these symptoms. Description comparison efficacy tolerability lozenges containing 20 mg ambroxol hydrochloride (trans-4-[(2-amino-3,5-dibrom-benzyl)amino]cyclohexano hydrochloride, CAS 18683-91-5) in relieving...

10.1055/s-0031-1299879 article EN Arzneimittelforschung 2011-12-26

The contribution of computerized impedance cardiography in monitoring and differentiating cardiovascular responses to pharmacologic stress after the administration dipyridamole (group 1, n = 24) or dobutamine 2, 26) was investigated during echocardiography. Heart rate, stroke volume index, cardiac index systemic vascular resistance were evaluated continuously with an automated, computerized, signal‐averaged system. Dipyridamole had little average effect on heart index. similar patients...

10.1177/009127009703700118 article EN The Journal of Clinical Pharmacology 1997-01-01

&lt;i&gt;Background:&lt;/i&gt; Respimat&lt;sup&gt;®&lt;/sup&gt;, a possible alternative to the conventional metered dose inhaler (MDI), is novel, reusable, propellant-free, multidose soft mist inhaler. Respimat slowly releases of active substance as with high proportion in fine particle fraction, leading improved lung deposition following inhalation when compared MDI. &lt;i&gt;Objectives and Methods:&lt;/i&gt; The equipotent bronchodilating efficacy safety combination fenoterol hydrobromide...

10.1159/000029515 article EN Respiration 2000-01-01
Coming Soon ...